

## Coldchain Delivery Systems Finalizes \$750,000 Definitive Agreement with Draganfly

Coldchain Delivery Systems, a Leading Medical and Vaccine Supply Chain Management Company to the US Government Selects Draganfly to Provide Medical and Vaccine Payload System and Flight Services

Los Angeles, CA. May 13, 2021 -- Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) ("Draganfly" or the "Company"), an award-winning, industry-leading drone solutions, and systems developer, is pleased to announce that Coldchain Technology Services, LLC ("Coldchain Delivery Systems") has signed a definitive agreement with Draganfly to develop, deploy and operate solutions for the delivery of medical supplies, medicine, and vaccines.

Coldchain Delivery Systems provides solutions for healthcare supply chain management for multiple governments and commercial clients, including the Defense Logistics Agency, the Centers for Disease Control and Prevention, Reserve Component forces, Johnson & Johnson brands, Chicago Department of Public Health, Texas Department of State Health Services, and others.

The definitive agreement provides for phase one of a planned five-phase roll-out for the comprehensive development, deployment, and operation of a medical drone delivery service as well as the development of a solution for the timely delivery of medical supplies, medicine, and vaccines. Phase one will also include working with various regulatory bodies, including the Federal Aviation Administration, to obtain licenses and approvals for initial non-commercial beta test delivery routes. Phase one has a value of \$125,000, to be executed over a maximum of ten months and the parties have agreed to negotiate an extension to the definitive agreement for phase two prior to the expiry of phase one. Under phase two, Coldchain Delivery Systems will commit to purchasing no less than USD\$625,000 in equipment and services from Draganfly.

"The partnership between Coldchain Delivery Systems and Draganfly will enable us to ensure delivery of medicine, supplies, and vaccines," said Wayne Williams Founder and Executive Director of Coldchain Delivery Systems. "Draganfly's commitment to enabling access to essential medical supplies by building an advanced payload system to accommodate our requirements is extremely exciting."

"We are excited to develop a payload system that will leverage our extensive patent portfolio as well as secured auto-pilot and flight management system", said Cameron Chell, CEO of Draganfly. "Coldchain Delivery Systems is a leader in healthcare supply chain management and we are looking forward to helping deliver via UAV medical supplies to remote areas."

## **About Coldchain Delivery Systems**

Coldchain Delivery Systems is the leader in time and temperature-sensitive medical material management integrating proven systems with the documentation fundamental to accreditation and effective Quality Control Systems. Coldchain Delivery Systems' remote monitoring system, prequalified thermal shippers, inventory control, fulfillment, and QAQC solutions ensure the Integrity and Security of its client's product. <a href="https://www.coldchain-tech.com">www.coldchain-tech.com</a>.

## **About Draganfly**

Draganfly Inc. (CSE: DFLY; OTCQB: DFLYF; FSE: 3U8) is the creator of quality, cutting-edge and software and systems that revolutionize the way organizations can do business and service their stakeholders. Recognized as being at the forefront of technology for over 22 years, Draganfly is an award-winning, industry-leading manufacturer and technology developer serving the public safety, agriculture, industrial inspections, security, and mapping and surveying markets. Draganfly is a company driven by passion, ingenuity, and the need to provide efficient solutions and first-class services to its customers around the world with the goal of saving time, money, and lives.

For more information on Draganfly, please visit us at <a href="www.draganfly.com">www.draganfly.com</a>.

For additional investor information, visit <a href="https://www.thecse.com/en/listings/technology/draganfly-inc">https://www.thecse.com/en/listings/technology/draganfly-inc</a>, <a href="https://www.boerse-frankfurt.de/aktie/draganfly-inc">https://www.boerse-frankfurt.de/aktie/draganfly-inc</a>, <a href="https://www.boerse-frankfurt.de/aktie/draganfly-inc">draganfly-inc</a>, <a href="https://www.boerse-frankfurt.de/aktie/draganfly-inc">https://www.boerse-frankfurt.de/aktie/draganfly-inc</a>, <a href="https://www.boerse-frankfurt.de/aktie/draganfly-inc/draganfly-inc/draganfly-inc/draganfly-inc/draganfly-inc/draganfly-inc/dra

Media Contact Arian Hopkins

email: media@draganfly.com

Company Contact

Email: info@draganfly.com

## **Forward-Looking Statements**

This release contains certain "forward looking statements" and certain "forward-looking information" as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "anticipate", "believe", "continue", "plans" or similar terminology. Forwardlooking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause the Company's actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out here in, including but not limited to: the potential impact of epidemics, pandemics or other public health crises, including the current outbreak of the novel coronavirus known as COVID-19 on the Company's business. operations and financial condition, the successful integration of technology, the inherent risks involved in the general securities markets; uncertainties relating to the availability and costs of financing needed in the future; the inherent uncertainty of cost estimates and the potential for unexpected costs and expenses, currency fluctuations; regulatory restrictions, liability, competition, loss of key employees and other related risks and uncertainties disclosed under the heading "Risk Factors" in the Company's most recent filings filed with securities regulators in Canada on the SEDAR website at www.sedar.com. The Company undertakes no obligation to update forwardlooking information except as required by applicable law. Such forward-looking information represents managements' best judgment based on information currently available. No forwardlooking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.